(R)-CR8

CHF 290.00
In stock
AG-MR-C0003-M01010 mgCHF 290.00
AG-MR-C0003-M05050 mgCHF 840.00
More Information
Product Details
Synonyms 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurine
Product Type Chemical
Properties
Formula

C24H29N7O

MW 431.5
CAS 294646-77-8
Purity Chemicals ≥98% (NMR)
Appearance White to off-white solid.
Solubility Soluble in DMSO or ethanol.
Reconstitution Stock solutions can be made up to 10mM in DMSO.
Identity Determined by 1H-NMR.
InChi Key HOCBJBNQIQQQGT-LJQANCHMSA-N
Smiles CC[C@H](CO)NC1=NC2=C(N=CN2C(C)C)C(NCC2=CC=C(C=C2)C2=NC=CC=C2)=N1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep under inert gas.
Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent and selective inhibitor of cyclin dependent kinases CDK1, CDK2, CDK5, CDK7 and CDK9.
  • Apoptosis inducer [1, 3, 4].
  • Inhibits the proliferation of various cancer cell lines [1].
  • Casein kinase 1 (CK1δ/ε) and glycogen synthase kinase (GSK-3α/β) inhibitor [1, 2].
  • Potential anti-inflammatory compound.
  • Potential antidiabetic compound.
Product References
  1. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases: K. Bettayeb, et al.; Oncogene 27, 5797 (2008)
  2. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1: N. Oumata, et al.; J. Med. Chem. 51, 5229 (2008)
  3. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells: K. Bettayeb, et al.; Genes Cancer 1, 369 (2010)
  4. CR8, a selective and potent CDK inhibitor, provides neuroprotection in experimental traumatic brain injury. S.V. Kabadi, et al.; Neurotherapeutics 9, 405 (2012)
  5. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells: E. Cosimo, et al.; Clin. Cancer Res. 19, 2393 (2013)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.